AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty
AbbVie inherited its status as a Dividend King, but it is building a strong foundation to continue the dividend streak.
Read the full articleYou might also wanna read
AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years
Barchart·9d ago
Is AbbVie Inc (ABBV) Overvalued After 4.2% Rally? GF Value Says Overvalued
Related Stocks: ABBV
GuruFocus·11h ago
AbbVie (ABBV) Gets $260 Price Target Upgrades Amid Growing Valuation Worries
AbbVie (ABBV) receives $260 price target upgrades from Citi and UBS, but Neutral ratings persist as Zacks flags Sell and valuation concerns
Blockonomi·1d ago
AbbVie (ABBV) Gets $260 Price Target Upgrade Despite Neutral Ratings and Valuation Red Flags
AbbVie (ABBV) receives $260 price target from Citi and UBS, but neutral ratings and Zacks Sell rank signal caution. Valuation concerns highl
parameter.io·1d ago
AbbVie Inc (ABBV) Stock Down 0.7% but Still Overvalued -- GF Score: 76/100
Related Stocks: ABBV
GuruFocus·6d ago
Business Watch: Evonik announces 3,200 job cuts; AbbVie acquires Apogee for $11 billion
Here’s what we’re watching in the chemical and pharmaceutical industries this week
cen.acs.org·21d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.